Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells

Tamoxifen (TAM) is widely used as an adjuvant therapy for women with breast cancer (BC). However, TAM possesses partial oestrogenic activity in the uterus and its use has been associated with an increased incidence of endometrial carcinoma (EC). The molecular mechanism for these observations is not...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Pandey, Vijay, Zhang, Min, Chong, Qing-Yun, You, Mingliang, Raquib, Ainiah Rushdiana, Pandey, Amit K., Liu, Dong-Xu, Liu, Liang, Ma, Lan, Jha, Sudhakar, Wu, Zheng-Sheng, Zhu, Tao, Lobie, Peter E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652779/
https://ncbi.nlm.nih.gov/pubmed/29100386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20461
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky